UA71895C2 - Use of intravenous contrast agents for projection mammography and device for projection mammography - Google Patents
Use of intravenous contrast agents for projection mammography and device for projection mammography Download PDFInfo
- Publication number
- UA71895C2 UA71895C2 UA2000010342A UA2000010342A UA71895C2 UA 71895 C2 UA71895 C2 UA 71895C2 UA 2000010342 A UA2000010342 A UA 2000010342A UA 2000010342 A UA2000010342 A UA 2000010342A UA 71895 C2 UA71895 C2 UA 71895C2
- Authority
- UA
- Ukraine
- Prior art keywords
- application according
- contrast
- contrast agent
- differs
- intravenous
- Prior art date
Links
- 239000002872 contrast media Substances 0.000 title claims abstract description 70
- 238000009607 mammography Methods 0.000 title claims abstract description 32
- 238000001990 intravenous administration Methods 0.000 title claims abstract description 20
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 20
- 229910052740 iodine Inorganic materials 0.000 claims description 20
- 239000011630 iodine Substances 0.000 claims description 20
- 230000005855 radiation Effects 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 16
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 15
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 15
- 229910052794 bromium Inorganic materials 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 12
- 230000037396 body weight Effects 0.000 claims description 11
- 239000013522 chelant Substances 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 26
- 230000003902 lesion Effects 0.000 abstract description 11
- 230000035945 sensitivity Effects 0.000 abstract description 10
- 238000003325 tomography Methods 0.000 abstract description 3
- 210000005075 mammary gland Anatomy 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 11
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 5
- 238000002591 computed tomography Methods 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000002583 angiography Methods 0.000 description 4
- 229910052797 bismuth Inorganic materials 0.000 description 4
- 159000000007 calcium salts Chemical class 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000013081 microcrystal Substances 0.000 description 3
- 238000002601 radiography Methods 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 229960002603 iopromide Drugs 0.000 description 2
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000011410 subtraction method Methods 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- XUHXFSYUBXNTHU-UHFFFAOYSA-N Iotrolan Chemical compound IC=1C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C=1N(C)C(=O)CC(=O)N(C)C1=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C1I XUHXFSYUBXNTHU-UHFFFAOYSA-N 0.000 description 1
- AMDBBAQNWSUWGN-UHFFFAOYSA-N Ioversol Chemical compound OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I AMDBBAQNWSUWGN-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001144280 Meadia Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 238000002083 X-ray spectrum Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 229960005423 diatrizoate Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229960004108 iobitridol Drugs 0.000 description 1
- YLPBXIKWXNRACS-UHFFFAOYSA-N iobitridol Chemical compound OCC(O)CN(C)C(=O)C1=C(I)C(NC(=O)C(CO)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I YLPBXIKWXNRACS-UHFFFAOYSA-N 0.000 description 1
- 229960004359 iodixanol Drugs 0.000 description 1
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 1
- 229960001025 iohexol Drugs 0.000 description 1
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 1
- 229960000780 iomeprol Drugs 0.000 description 1
- NJKDOADNQSYQEV-UHFFFAOYSA-N iomeprol Chemical compound OCC(=O)N(C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NJKDOADNQSYQEV-UHFFFAOYSA-N 0.000 description 1
- 229960004647 iopamidol Drugs 0.000 description 1
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 description 1
- 229960000824 iopentol Drugs 0.000 description 1
- IUNJANQVIJDFTQ-UHFFFAOYSA-N iopentol Chemical compound COCC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I IUNJANQVIJDFTQ-UHFFFAOYSA-N 0.000 description 1
- 229960003182 iotrolan Drugs 0.000 description 1
- 229960004537 ioversol Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000007487 urography Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0457—Semi-solid forms, ointments, gels, hydrogels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Detergent Compositions (AREA)
- Percussion Or Vibration Massage (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Liquid Crystal (AREA)
- Holo Graphy (AREA)
- Video Image Reproduction Devices For Color Tv Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97250190A EP0885616A1 (de) | 1997-06-20 | 1997-06-20 | Verwendung von intravenösen Kontrastmitteln sowie Vorrichtungen für die Projektionsmammographie |
| PCT/EP1998/003658 WO1998058679A1 (de) | 1997-06-20 | 1998-06-19 | Verwendung von intravenösen kontrastmitteln für die projektionsmammographie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA71895C2 true UA71895C2 (en) | 2005-01-17 |
Family
ID=8229158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2000010342A UA71895C2 (en) | 1997-06-20 | 1998-06-19 | Use of intravenous contrast agents for projection mammography and device for projection mammography |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20020031475A1 (xx) |
| EP (3) | EP0885616A1 (xx) |
| JP (3) | JP4664449B2 (xx) |
| KR (2) | KR20010013980A (xx) |
| CN (2) | CN1263449A (xx) |
| AT (1) | ATE229820T1 (xx) |
| AU (2) | AU8337998A (xx) |
| BG (2) | BG104018A (xx) |
| BR (2) | BR9810205A (xx) |
| CA (2) | CA2294187A1 (xx) |
| CZ (1) | CZ298462B6 (xx) |
| DE (1) | DE59806743D1 (xx) |
| DK (1) | DK0994729T3 (xx) |
| HK (1) | HK1029759A1 (xx) |
| HU (2) | HUP0003096A1 (xx) |
| IL (2) | IL133573A0 (xx) |
| NO (2) | NO315638B1 (xx) |
| NZ (2) | NZ501603A (xx) |
| PL (2) | PL191807B1 (xx) |
| RS (1) | RS49734B (xx) |
| RU (1) | RU2194533C2 (xx) |
| SI (2) | SI20148A (xx) |
| SK (2) | SK181199A3 (xx) |
| TR (2) | TR199903144T2 (xx) |
| UA (1) | UA71895C2 (xx) |
| WO (2) | WO1998058679A1 (xx) |
| YU (1) | YU66299A (xx) |
| ZA (1) | ZA985395B (xx) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10118792B4 (de) * | 2001-04-05 | 2005-12-22 | Schering Ag | Anordnung zur Aufnahme von Projektionsmammogrammen und Verwendung der Anordnung für die Projektionsmammographie |
| FR2823969B1 (fr) * | 2001-04-30 | 2003-12-26 | Ge Med Sys Global Tech Co Llc | Procede de prelevement d'un tissu au cours d'un examen par rayons x et dispositif de mise en oeuvre |
| DE102005033235A1 (de) * | 2005-07-15 | 2007-01-18 | Siemens Ag | Verfahren zur Visualisierung eines vaskulären Einsatzstücks |
| US20080167552A1 (en) * | 2007-01-04 | 2008-07-10 | General Electric Company | System and method of generating an image of a contrast agent injected into an imaged subject |
| FR2927719B1 (fr) * | 2008-02-19 | 2010-03-26 | Gen Electric | Procede de traitement d'images obtenues par tomosynthese et dispositif associe |
| US8315449B2 (en) * | 2008-06-24 | 2012-11-20 | Medrad, Inc. | Identification of regions of interest and extraction of time value curves in imaging procedures |
| JP2012055549A (ja) * | 2010-09-10 | 2012-03-22 | Fujifilm Corp | バイオプシ用ファントム |
| FR2967888B1 (fr) * | 2010-11-26 | 2012-12-21 | Gen Electric | Procede de galactographie et mammographe pour l'execution dudit procede |
| US9651138B2 (en) | 2011-09-30 | 2017-05-16 | Mtd Products Inc. | Speed control assembly for a self-propelled walk-behind lawn mower |
| DE102012217301B4 (de) | 2012-09-25 | 2021-10-14 | Bayer Pharma Aktiengesellschaft | Kombination aus Kontrastmittel und Mammographie-CT-System mit vorgegebenem Energiebereich und Verfahren zur Erzeugung tomographischer Mammographie-CT-Aufnahmen durch diese Kombination |
| EA036245B1 (ru) * | 2017-10-26 | 2020-10-16 | Казахский научно-исследовательский институт онкологии и радиологии | Способ диагностики рака молочной железы |
| EP3498306A1 (de) * | 2017-12-16 | 2019-06-19 | Bionorica SE | Extrakte aus vitex agnus castus zur behandlung und diagnose von brustkrebs |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4192859A (en) * | 1978-09-29 | 1980-03-11 | E. R. Squibb & Sons, Inc. | Contrast media containing liposomes as carriers |
| FR2541272A1 (fr) * | 1983-02-23 | 1984-08-24 | Guerbet Sa | Composes bromes et produits opacifiants en contenant |
| WO1987002893A1 (en) * | 1985-11-18 | 1987-05-21 | Board Of Regents, The University Of Texas System | Polychelating agents for image and spectral enhancement (and spectral shift) |
| US5260050A (en) * | 1988-09-29 | 1993-11-09 | Ranney David F | Methods and compositions for magnetic resonance imaging comprising superparamagnetic ferromagnetically coupled chromium complexes |
| GB8906130D0 (en) * | 1989-03-17 | 1989-05-04 | Nycomed As | Compositions |
| DE3938992A1 (de) * | 1989-11-21 | 1991-05-23 | Schering Ag | Kaskadenpolymer-gebundene komplexbildner, deren komplexe und konjugate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel |
| US5844965A (en) * | 1989-11-24 | 1998-12-01 | Thomas Jefferson University | Method and apparatus for using film density measurements of a radiograph to monitor the reproducibility of X-ray exposure parameters of a mammography unit |
| DE4232925A1 (de) * | 1992-09-28 | 1994-03-31 | Diagnostikforschung Inst | 3-,8-substituierte Deuteroporphyrinderivate, diese enthaltende pharmazeutische Mittel und Verfahren zu ihrer Herstellung |
| US5411730A (en) * | 1993-07-20 | 1995-05-02 | Research Corporation Technologies, Inc. | Magnetic microparticles |
| DE4417628C1 (de) * | 1994-05-19 | 1995-09-28 | Siemens Ag | Verfahren zur adaptiven Rauschverminderung für digitale Bildsequenzen |
| CA2206558A1 (en) * | 1994-11-30 | 1996-06-06 | Schering Aktiengesellschaft | Use of metal complexes as x-ray diagnostic agents for the liver and gallbladder |
| US5756066A (en) * | 1995-06-07 | 1998-05-26 | Schering Aktiengesellschaft | Iodine-containing peptides |
| US5804164A (en) * | 1996-03-13 | 1998-09-08 | Research Corporation Technologies, Inc. | Water-soluble lipophilic contrast agents |
| US6009342A (en) * | 1997-02-28 | 1999-12-28 | The Regents Of The University Of California | Imaging method for the grading of tumors |
-
1997
- 1997-06-20 EP EP97250190A patent/EP0885616A1/de not_active Withdrawn
-
1998
- 1998-06-19 CA CA002294187A patent/CA2294187A1/en not_active Abandoned
- 1998-06-19 KR KR19997012006A patent/KR20010013980A/ko not_active Application Discontinuation
- 1998-06-19 CN CN98807066A patent/CN1263449A/zh active Pending
- 1998-06-19 BR BR9810205-2A patent/BR9810205A/pt not_active Application Discontinuation
- 1998-06-19 EP EP98933626A patent/EP0991356A1/de not_active Withdrawn
- 1998-06-19 ZA ZA985395A patent/ZA985395B/xx unknown
- 1998-06-19 UA UA2000010342A patent/UA71895C2/uk unknown
- 1998-06-19 YU YU66299A patent/YU66299A/sh unknown
- 1998-06-19 TR TR1999/03144T patent/TR199903144T2/xx unknown
- 1998-06-19 AU AU83379/98A patent/AU8337998A/en not_active Abandoned
- 1998-06-19 CN CNB988070677A patent/CN1212862C/zh not_active Expired - Fee Related
- 1998-06-19 SK SK1811-99A patent/SK181199A3/sk unknown
- 1998-06-19 SI SI9820042A patent/SI20148A/sl unknown
- 1998-06-19 KR KR1019997012005A patent/KR100582980B1/ko not_active IP Right Cessation
- 1998-06-19 IL IL13357398A patent/IL133573A0/xx unknown
- 1998-06-19 US US09/446,328 patent/US20020031475A1/en not_active Abandoned
- 1998-06-19 DE DE59806743T patent/DE59806743D1/de not_active Expired - Lifetime
- 1998-06-19 EP EP98937494A patent/EP0994729B1/de not_active Expired - Lifetime
- 1998-06-19 TR TR1999/03140T patent/TR199903140T2/xx unknown
- 1998-06-19 AT AT98937494T patent/ATE229820T1/de not_active IP Right Cessation
- 1998-06-19 SI SI9820041A patent/SI20152A/sl not_active IP Right Cessation
- 1998-06-19 NZ NZ501603A patent/NZ501603A/en unknown
- 1998-06-19 PL PL337287A patent/PL191807B1/pl not_active IP Right Cessation
- 1998-06-19 SK SK1712-99A patent/SK282716B6/sk not_active IP Right Cessation
- 1998-06-19 AU AU86271/98A patent/AU747033B2/en not_active Ceased
- 1998-06-19 DK DK98937494T patent/DK0994729T3/da active
- 1998-06-19 CZ CZ0460999A patent/CZ298462B6/cs not_active IP Right Cessation
- 1998-06-19 PL PL98337286A patent/PL337286A1/xx unknown
- 1998-06-19 IL IL13357498A patent/IL133574A/en not_active IP Right Cessation
- 1998-06-19 HU HU0003096A patent/HUP0003096A1/hu unknown
- 1998-06-19 HU HU0003097A patent/HU225522B1/hu not_active IP Right Cessation
- 1998-06-19 BR BR9810215-0A patent/BR9810215A/pt not_active Application Discontinuation
- 1998-06-19 RS YUP-661/99A patent/RS49734B/sr unknown
- 1998-06-19 JP JP50374199A patent/JP4664449B2/ja not_active Expired - Fee Related
- 1998-06-19 WO PCT/EP1998/003658 patent/WO1998058679A1/de active IP Right Grant
- 1998-06-19 CA CA002294502A patent/CA2294502C/en not_active Expired - Fee Related
- 1998-06-19 NZ NZ501602A patent/NZ501602A/en unknown
- 1998-06-19 JP JP50374299A patent/JP2002504843A/ja active Pending
- 1998-06-19 RU RU2000101332/14A patent/RU2194533C2/ru not_active IP Right Cessation
- 1998-06-19 WO PCT/EP1998/003659 patent/WO1998058585A1/de not_active Application Discontinuation
-
1999
- 1999-12-15 BG BG104018A patent/BG104018A/xx unknown
- 1999-12-15 BG BG104017A patent/BG64895B1/bg unknown
- 1999-12-17 NO NO19996291A patent/NO315638B1/no not_active IP Right Cessation
- 1999-12-17 NO NO996292A patent/NO996292L/no not_active Application Discontinuation
-
2001
- 2001-01-29 HK HK01100622A patent/HK1029759A1/xx not_active IP Right Cessation
-
2004
- 2004-05-24 US US10/851,213 patent/US20050008574A1/en not_active Abandoned
-
2010
- 2010-10-01 JP JP2010223769A patent/JP2011012074A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sagel et al. | Early clinical experience with motionless whole-body computed tomography | |
| AU2006254747A1 (en) | X-ray arrangement for the image representation of an examination object and use of the X-ray arrangement | |
| Klein et al. | Computed tomographic cholangiography using spiral scanning and 3D image processing | |
| JP2011012074A (ja) | 乳房投射撮影用静脈内造影剤の使用および装置 | |
| US20070025514A1 (en) | X-ray arrangement for graphic display of an object under examination and use of the x-ray arrangement | |
| US20170095578A1 (en) | Ct scans using gadolinium-based contrast agent | |
| Chen et al. | Scope of diagnostic imaging | |
| Kan et al. | High Z elements in human sarcomata: assessment by multienergy CT and neutron activation analysis | |
| RU2772636C1 (ru) | Способ обследования пациентов с подозрением на воспаление в стенке аневризматически расширенной восходящей аорты | |
| Patronas et al. | Brain-tumor imaging using radiopaque perfluorocarbon: A preliminary report | |
| Nair et al. | Imaging techniques | |
| Sommer et al. | Contrast resolution of line-scanned digital radiography | |
| MXPA99011339A (en) | Device for projection mammography | |
| CZ461099A3 (cs) | Zařízení pro projekční mamografii | |
| AlObaidy et al. | Basic principles of radiologic modalities | |
| Hübener et al. | Digital Radiography (Scanning Projection): Possibilities and Perspectives | |
| MXPA99011508A (en) | Use of intravenous contrast agents and devices for projection mammography |